BioNxt Solutions (BNXT) AI Stock Analysis

• Market Cap: C$70.65M
• Dividend Yield: N/A
• Average Volume (3M): 80.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.68
• Revenue Growth: -62.34%
• EPS Growth: 9.80%
• Country: CA
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 121,810,260
• 10 Day Avg. Volume: 59,081
• 30 Day Avg. Volume: 80,860
• PEG Ratio: 0.20
• Price to Book (P/B): -5.39
• Price to Sales (P/S): 1568.84
• P/FCF Ratio: -13.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.58 ▼(-10.00% Downside)

The score is driven mainly by very weak financial performance (losses, negative equity, rising debt, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Valuation is difficult to assess given negative earnings and no dividend support, providing limited offset.

Positive Factors

Reduced cash burn trend

The company reports that losses and cash burn have moderated versus the weakest 2021–2022 period. A sustained reduction in cash outflow pace can extend runway, lower near-term refinancing pressure, and provide management time to execute restructuring or commercialization plans.

Lean cost base

A very small headcount suggests a lean operating model, which can conserve cash and allow flexibility in scaling R&D or commercialization spending. For a cash‑burning biotech/specialty drug firm, low fixed cost structure materially lengthens runway per financing round.

Industry structural demand

Operating in specialty and generic pharmaceuticals exposes the firm to durable demand for essential medicines and recurring revenue opportunities. Structural industry needs, regulatory barriers to entry, and long product lifecycles can support sustained revenue once products reach stable commercialization.

Negative Factors

Negative shareholders' equity

Negative equity denotes solvency pressure and limited balance sheet flexibility. It raises refinancing and dilution risk, constrains access to conventional credit, and signals that accumulated losses have materially eroded investor capital—impairing long‑term financial resilience.

Persistent operating cash burn

Continued negative operating and free cash flow indicates the business cannot self‑fund operations and must rely on external financing. Over months this amplifies dilution or refinancing risk, limits strategic optionality, and pressures management to secure funding rather than invest in growth.

Sharply declining revenue

Material year‑over‑year revenue decline undermines the path to sustainable profitability and scaling. Falling top line reduces leverage to cover fixed costs, lengthens time to breakeven, and impairs investor confidence in commercial viability absent clear product or market inflection catalysts.

BioNxt Solutions Business Overview & Revenue Model

Company Description

BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

How the Company Makes Money

BioNxt Solutions generates revenue through a multi-faceted approach that includes the sale of proprietary diagnostic assays and biopharmaceutical products. The company earns income from direct product sales to healthcare providers and research institutions, as well as through licensing agreements with pharmaceutical companies for its technologies. Additionally, BNXT may engage in collaborative research initiatives with industry partners, which can lead to milestone payments and royalties on future product sales. Strategic partnerships with established players in the biotechnology and pharmaceutical sectors further enhance its revenue potential by expanding market access and increasing product visibility.

BioNxt Solutions Financial Statement Overview

Summary

Financial health is very weak: minimal and declining TTM revenue (~-27% YoY), deeply negative profitability, negative shareholders’ equity (solvency risk), rising debt, and persistent negative operating/free cash flow indicating ongoing reliance on external funding. Losses/cash burn have moderated versus earlier years, but overall risk remains high.

Income Statement

Performance remains very weak. Revenue in TTM (Trailing-Twelve-Months) is minimal and down sharply (about -27% year-over-year), and profitability is deeply negative with large operating losses and an extremely negative net margin. While losses have narrowed versus the very weak 2021–2022 period, the business still has not shown a credible path to operating breakeven based on the current revenue and margin profile.

Balance Sheet

The balance sheet is highly stressed. Shareholders’ equity is negative in the most recent periods, which raises solvency risk and limits financial flexibility, while total debt has increased materially versus prior years. With negative equity, traditional leverage signals are unfavorable and refinancing/dilution risk is elevated despite a relatively small asset base.

Cash Flow

Cash burn remains significant. Operating cash flow and free cash flow are negative across all shown periods, including TTM (Trailing-Twelve-Months), indicating continued reliance on external funding. A positive free cash flow growth rate mainly reflects a reduced pace of cash outflow versus the prior year, but the company is still far from self-funding operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.82K	26.98K	372.25K	297.44K	286.50K	345.65K
Gross Profit	-12.51K	26.98K	372.25K	195.62K	199.48K	345.65K
EBITDA	-4.95M	-4.32M	-6.48M	-11.51M	-19.19M	-16.05M
Net Income	-6.18M	-5.31M	-7.72M	-12.38M	-20.64M	-16.89M
Balance Sheet
Total Assets	1.23M	569.36K	1.27M	1.61M	9.73M	8.28M
Cash, Cash Equivalents and Short-Term Investments	468.76K	32.35K	363.65K	136.20K	1.35M	2.58M
Total Debt	8.33M	4.28M	4.89M	4.37M	5.46M	3.31M
Total Liabilities	9.54M	8.43M	6.55M	5.74M	8.06M	4.28M
Stockholders Equity	-8.31M	-7.86M	-5.28M	-4.13M	1.67M	4.01M
Cash Flow
Free Cash Flow	-5.18M	-3.03M	-5.37M	-6.23M	-12.61M	-10.36M
Operating Cash Flow	-5.18M	-3.03M	-5.17M	-6.23M	-12.16M	-10.20M
Investing Cash Flow	83.63K	56.21K	100.84K	-3.86K	-5.31M	-156.47K
Financing Cash Flow	5.49M	2.64M	5.29M	5.02M	16.23M	12.65M

BioNxt Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BNXT, the sentiment is Negative. The current price of 0.64 is above the 20-day moving average (MA) of 0.54, above the 50-day MA of 0.61, and below the 200-day MA of 0.68, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.01 is Neutral, neither overbought nor oversold. The STOCH value of 54.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BNXT.

BioNxt Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATLE	50 Neutral	C$54.59M	-2.71	-19.76%	―	26.91%	81.01%
AVCN	46 Neutral	C$21.82M	-11.28	-77.67%	―	2.41%	74.61%
INNO	46 Neutral	C$32.08M	-7.13	-71.80%	―	-3.94%	-17.62%
LABS	45 Neutral	C$29.45M	-3.63	-19.10%	―	18.06%	34.58%
BNXT	42 Neutral	C$70.65M	-10.86	―	―	-62.34%	9.80%

BioNxt Solutions Corporate Events

BioNxt Moves to Retire $2.7 Million in Debenture Debt via Share Issuance

BioNxt Solutions Inc. has proposed a shares-for-debt transaction with arm’s length creditors to extinguish approximately $2.7 million in outstanding obligations arising from 8% convertible debentures issued in December 2022. In full settlement of the principal and accrued interest, the company plans to issue 6,008,883 common shares at a deemed price of $0.45 per share, subject to customary conditions and a statutory four-month-and-one-day hold period under Canadian securities regulations, a move that will strengthen its balance sheet by converting debt into equity but dilute existing shareholders.

The most recent analyst rating on (TSE:BNXT) stock is a Sell with a C$0.41 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt’s Sublingual Cladribine Film Delivers 40% Higher Exposure in Preclinical MS Study

BioNxt Solutions has reported final results from a preclinical study in miniature pigs showing that its proprietary sublingual oral dissolvable film formulation of cladribine for multiple sclerosis achieved approximately 40% higher systemic drug exposure over 48 hours compared with a conventional oral tablet formulation. Using AUC (0–48 h) as the key pharmacokinetic measure, the sublingual film delivered a mean exposure of 39.46 ng·h/mL versus 28.11 ng·h/mL for tablets, supporting the efficiency of its transmucosal delivery approach and helping to de-risk advancement into human pharmacokinetic trials, with potential implications for dose optimization, improved tolerability and a more competitive positioning against existing MS treatments.

The most recent analyst rating on (TSE:BNXT) stock is a Sell with a C$0.48 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt’s Cladribine Film Shows Superior Bioavailability in Preclinical MS Study

BioNxt Solutions has reported successful results from a comparative pharmacokinetics study in pigs showing that its proprietary sublingual cladribine orally dissolving film delivers superior bioavailability versus the standard name-brand tablet used to treat Multiple Sclerosis. The enhanced absorption seen in the large-animal model supports the potential to achieve therapeutic exposure with lower systemic drug levels, which could reduce dose-related side effects, improve patient tolerability—especially for those with swallowing difficulties—and optimize dosing for an upcoming human bioequivalence study, positioning BioNxt’s ODF platform as a differentiated entrant in a fast-growing, multibillion-dollar MS drug market.

The most recent analyst rating on (TSE:BNXT) stock is a Sell with a C$0.48 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Advances Thin-Film Drug Platform With First Patent for Sublingual Cladribine

BioNxt Solutions has reported significant progress in developing its proprietary rapid-dissolving, “melt-in-your-mouth” thin-film drug delivery platform to address dysphagia, a widespread problem that affects up to 40% of adults and nearly half of multiple sclerosis patients, and that undermines adherence in large autoimmune markets such as MS, myasthenia gravis, lupus nephritis and rheumatoid arthritis. The company has secured its first national-level patent for BNT23001, a sublingual cladribine film for MS and MG, via a newly granted Eurasian patent valid through 2043 covering more than 200 million people, completed GMP clinical batch manufacturing, and is preparing a comparative human bioequivalence study for early 2026, positioning the product for an accelerated, lower-risk regulatory pathway and creating a foundation for broader commercialization and global IP expansion across key autoimmune drug markets.

The most recent analyst rating on (TSE:BNXT) stock is a Sell with a C$0.48 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Signs Agreement for Sublingual Chemotherapy and Immunosuppressant Innovation

BioNxt Solutions Inc. has entered into a letter agreement to co-develop a novel sublingual drug formulation for chemotherapy and immunosuppressant treatments, securing exclusive intellectual property rights in collaboration with a European-based chemotherapy company. The partnership involves prototype development and regulatory progression, with expected provisional patent filings by year-end. This initiative aligns with BioNxt’s broader portfolio goals and takes advantage of a growing immunosuppressant market projected to reach USD 61.05 billion by 2025.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$0.69 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Secures Eurasian Patent for Sublingual Cladribine Platform

BioNxt Solutions Inc. has secured a final patent grant from the Eurasian Patent Organization for its sublingual thin-film cladribine platform, marking a significant milestone in its strategic global intellectual property expansion. The patent, valid until June 2043, protects the formulation across eight Eurasian countries with a population exceeding 200 million, highlighting BioNxt’s push for commercialization and partnership opportunities. BioNxt is advancing patent efforts in major pharmaceutical markets such as the EU, US, Canada, and Japan, aiming to bolster its position within the healthcare industry and enhance treatment outcomes globally.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$0.69 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Unveils Innovative Oral Film to Transform MS Treatment

BioNxt Solutions is advancing its proprietary ‘Melt in Your Mouth’ cladribine film for multiple sclerosis (MS) patients who struggle with swallowing tablets, a common but under-recognized issue known as dysphagia. By offering this innovative sublingual drug-delivery format, BioNxt aims to improve treatment adherence, safety, and accessibility. Positioned within growing global markets for cladribine and oral transmucosal technologies, this development enhances the company’s competitive standing and addresses a significant unmet need in MS treatment.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$0.69 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Secures Eurasian Patent Readiness for Sublingual Drug Delivery

BioNxt Solutions Inc. has received a ‘Readiness to Grant’ notification from the Eurasian Patent Organization for its patent application on sublingual delivery of anticancer drugs, specifically for treating autoimmune neurodegenerative diseases. This development is a significant step in BioNxt’s commercialization strategy, as it prepares for a large-mass animal bioequivalence study and further international patent nationalization, enhancing its intellectual property portfolio and market positioning in key global regions.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Secures European Patent for Innovative MS Treatment

BioNxt Solutions Inc. has received an ‘Intention to Grant’ notification from the European Patent Office for its sublingual thin-film formulation of cladribine, aimed at treating multiple sclerosis and related diseases. This patent, along with others in Eurasia, strengthens BioNxt’s position in the global market for oral drug delivery, aligning with the trend towards patient-friendly therapies in the European MS market, which is projected to grow significantly. The company’s innovative formulation offers a convenient, non-invasive alternative to traditional treatments, potentially improving patient adherence and quality of life.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Solutions Completes Debt Settlement to Strengthen Financial Position

BioNxt Solutions Inc. has successfully completed a debt settlement with an arm’s length creditor, resolving $225,010 in debt through the issuance of 112,505 common shares and a cash payment of $112,505. This strategic move helps BioNxt manage its financial obligations while maintaining focus on its core operations and market expansion efforts.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Solutions Advances Cladribine Formulation with New Study

BioNxt Solutions has initiated a large-mass animal bioequivalence study for its lead product, BNT23001, a sublingual Cladribine formulation for multiple sclerosis treatment. This study aims to optimize dosing parameters for an upcoming human bioequivalence study planned for early 2026, potentially enhancing the product’s market positioning by improving drug absorption and patient compliance. The company is also advancing patent nationalization in key global markets, with favorable communications from European and Eurasian patent offices, indicating strong intellectual property protection.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.